Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
World game at war: why some European nations have threatened a World Cup boycott 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
REDWOOD CITY, Calif., April 19, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective April 19, 2018, the compensation committee of the company’s board of directors granted 9 new employees options to purchase an aggregate of 187,000 shares of the company’s common stock with a per share exercise price of $12.05, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
